Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Thromb Res. 2018 Sep;169:123-127. doi: 10.1016/j.thromres.2018.07.022. Epub 2018 Jul 19.

Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review.

Author information

1
Department of Cardiology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands; Department of Emergency Medicine, Medical Centre Leeuwarden, Leeuwarden, the Netherlands. Electronic address: h.lameijer@umcg.nl.
2
Department of Cardiology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
3
Department of Haematology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.

Abstract

Introduction:

Direct oral anticoagulants (DOACs) are increasingly used for anticoagulation or prevention of thromboembolic events in conditions that may co-occur with pregnancy. However, evidence regarding efficacy and safety during pregnancy is scarce.

Aim:

To review the current literature concerning the efficacy, safety and outcome of DOACs during pregnancy in humans.

Methods:

We systematically searched the MedLine public database for all studies describing the use of DOACs during pregnancy published up to July 4th 2017.

Results:

236 cases of DOAC use during pregnancy were reported. Rivaroxaban was the most reported DOAC (n = 178). DOACs were mostly used for prophylaxis or treatment of venous thromboembolism (n = 91). DOACs were discontinued within the first 2 months of pregnancy in 84%, maximum reported duration of use was 26 weeks. Pregnancy outcome data were available for 140 pregnancies. Thirty-nine pregnancies were electively terminated. In the remaining 101 pregnancies total miscarriage rate was 31% (n = 31) and live birth rate was 68% (n = 69, 1 missing). Foetal and neonatal abnormalities were reported in 8 pregnancies, of which at least half were suspected to be related to rivaroxaban use during the 1st trimester of pregnancy. In only 18% of cases (n = 42), the presence or absence of thrombotic and bleeding complications was reported.

Conclusion:

The limited available evidence raises concern regarding embryo-foetal safety, with high incidence of miscarriages and a 4% rate of anomalies with the use of rivaroxaban. Not enough data are available to judge safety and efficacy of the use of DOACs during pregnancy.

PMID:
30036784
DOI:
10.1016/j.thromres.2018.07.022
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center